文献速递临床试验与 GCP

阿奇霉素对异基因造血干细胞移植后无气流下降生存的影响:ALLOZITHRO随机临床试验

Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

ALLOZITHRO平行组试验在19个法国学术移植中心纳入480例因血液系统恶性肿瘤接受异基因造血干细胞移植的患者,随机接受阿奇霉素250 mg每周3次(n=243)或安慰剂(n=237)共2年。2年无气流下降生存率阿奇霉素组32.8% vs 安慰剂组41.3%(未校正HR 1.3,95%CI 1.02-1.70,P=0.03),阿奇霉素组死亡率更高(2年生存率56.6% vs 70.1%,未校正HR 1.5,95%CI 1.1-2.0,P=0.02)。结论:早期使用阿奇霉素导致无气流下降生存更差,但受试验提前终止限制。

要点

  • 异基因HSCT后早期使用阿奇霉素2年无气流下降生存率32.8%,低于安慰剂组的41.3%(未校正HR 1.3,95%CI 1.02-1.70,P=0.03)。
  • 阿奇霉素组2年生存率56.6%,低于安慰剂组的70.1%(未校正HR 1.5,95%CI 1.1-2.0,P=0.02)。
  • 事后分析中阿奇霉素组2年血液学复发累积发生率33.5%,高于安慰剂组的22.3%(未校正病因特异性HR 1.7,95%CI 1.2-2.4,P=0.002)。

核心结论

  • 在接受异基因造血干细胞移植的血液系统恶性肿瘤患者中,早期使用阿奇霉素导致无气流下降生存劣于安慰剂,但该结果受试验提前终止限制。
  • 与复发相关的潜在危害需要进一步研究。

研究设计与样本

  • ALLOZITHRO平行组随机临床试验,在19个法国学术移植中心开展。
  • 纳入至少16岁、因血液系统恶性肿瘤接受异基因造血干细胞移植且有移植前肺功能检查结果的患者,入组时间为2014年2月至2015年8月,随访至2017年4月26日。
  • 患者随机接受阿奇霉素250 mg每周3次(n=243)或安慰剂(n=237)共2年,从预处理方案开始时用药。
  • 480例随机患者中465例(97%)纳入改良意向治疗分析(平均年龄52岁[SD 14],女性75例[35%])。

主要发现

  • 入组13个月后,独立数据与安全监察委员会发现盲态分组间血液学复发例数出现非预期不平衡,治疗于2016年12月26日停止。
  • 数据截止时104例患者(22%;阿奇霉素组54例 vs 安慰剂组50例)发生气流下降,138例患者(30%)死亡(阿奇霉素组78例 vs 安慰剂组60例)。
  • 2年无气流下降生存率阿奇霉素组32.8%(95%CI 25.9%-41.7%)vs 安慰剂组41.3%(95%CI 34.1%-50.1%)(未校正HR 1.3,95%CI 1.02-1.70,P=0.03)。
  • 发生闭塞性细支气管炎综合征的22例患者(5%)中,阿奇霉素组15例(6%)vs 安慰剂组7例(3%)(P=0.08)。
  • 阿奇霉素组死亡率增加,2年生存率56.6%(95%CI 50.2%-63.7%)vs 安慰剂组70.1%(95%CI 64.2%-76.5%)(未校正HR 1.5,95%CI 1.1-2.0,P=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些发现受试验提前终止限制。
  • 与复发相关的潜在危害需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome. OBJECTIVE: To evaluate if the early administration of azithromycin can improve airflow decline-free survival after allogeneic HSCT. DESIGN, SETTING, AND PARTICIPANTS: The ALLOZITHRO parallel-group trial conducted in 19 French academic transplant centers and involving participants who were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available pretransplant pulmonary function test results. Enrollment was from February 2014 to August 2015 with follow-up through April 26, 2017. INTERVENTIONS: Patients were randomly assigned to receive 3 times a week either 250 mg of azithromycin (n = 243) or placebo (n = 237) for 2 years, starting at the time of the conditioning regimen. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was airflow decline-free survival at 2 years after randomization. Main secondary end points were overall survival and bronchiolitis obliterans syndrome at 2 years. RESULTS: Thirteen months after enrollment, the independent data and safety monitoring board detected an unanticipated imbalance across blinded groups in the number of hematological relapses, and the treatment was stopped December 26, 2016. Among 480 randomized participants, 465 (97%) were included in the modified intention-to-treat analysis (mean age, 52 [SD, 14] years; 75 women [35%]). At the time of data cutoff, 104 patients (22%; 54 azithromycin vs 50 placebo) had experienced an airflow decline; 138 patients (30%) died (78 azithromycin vs 60 placebo). Two-year airflow decline-free survival was 32.8% (95% CI, 25.9%-41.7%) with azithromycin and 41.3% (95% CI, 34.1%-50.1%) with placebo (unadjusted hazard ratio [HR], 1.3; 95% CI, 1.02-1.70; P = .03). Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin group and 7 (3%) in the placebo group (P = .08). The azithromycin group had increased mortality, with a 2-year survival of 56.6% (95% CI, 50.2%-63.7%) vs 70.1% (95% CI, 64.2%-76.5%) in the placebo group (unadjusted HR, 1.5; 95% CI, 1.1-2.0; P = .02). In a post hoc analysis, the 2-year cumulative incidence of hematological relapse was 33.5% (95% CI, 27.3%-39.7%) with azithromycin vs 22.3% (95% CI, 16.4%-28.2%) with placebo (unadjusted cause-specific HR, 1.7; 95% CI, 1.2-2.4; P = .002). CONCLUSIONS AND RELEVANCE: Among patients undergoing allogeneic HSCT for hematological malignancy, early administration of azithromycin resulted in worse airflow decline-free survival than did placebo; these findings are limited by early trial termination. The potential for harm related to relapse requires further investigation. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01959100.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Bergeron A, Chevret S, Granata A, et al. Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial. JAMA. 2017. PMID: 28787506. doi:10.1001/jama.2017.9938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。